US court blocks Bayer from selling an agricultural weed killer in America

The company faces separate allegations that its glyphosate-based weed killer Roundup causes cancer

Bayer
The Bayer AG logo sits on display at the headquarters in La Garenne-Colombes, near Paris, France. Photo: Reuters
Tom Polansek, Ludwig Burger & Sabahatjahan Contractor | Reuters Washington
3 min read Last Updated : Jun 05 2020 | 6:55 AM IST
A US appeals court has blocked Bayer AG from selling an agricultural weed killer in the United States, the latest setback for a business already fighting an expensive legal battle over another product.

A three-judge panel of the 9th US Circuit Court of Appeals ruled the US Environmental Protection Agency substantially understated the risks related to the use of dicamba, a chemical found in herbicides sold by Bayer and rivals that are sprayed on genetically engineered soybeans and cotton. The herbicides are known to drift away and damage other crops that are not resistant.

The lawsuit was among those German-based Bayer inherited when it bought Monsanto for $63 billion in 2018. The company faces separate allegations that its glyphosate-based weed killer Roundup causes cancer.


Environmental groups have sought cancellation of the EPA's approval of Monsanto's dicamba-based XtendiMax herbicide, arguing it harms nearby plants and wildlife.

The court agreed, and its ruling, issued on Wednesday, also blocks sales of dicamba-based herbicides like BASF's Engenia and Corteva Agriscience's FeXapan.

Bayer and BASF said they disagreed with the judgment. Corteva said it was reviewing the decision and believed dicamba could be used safely.

Shares in Bayer fell 4%, while BASF's stock recovered after initial losses and Corteva's stock rose 3%.

Bayer said the ruling related to the agency's 2018 registration decision that expires in December and that it was seeking new EPA registration for the herbicide for 2021 and beyond. The EPA said it was reviewing the court's decision and would move promptly to address its order.

"Depending upon actions by the EPA and whether the ruling is successfully challenged, we will work quickly to minimize any impact on our customers this season," Bayer said.

Ruling Praised, Criticised

US Agriculture Secretary Sonny Perdue criticized the ruling and said it was unclear if farmers who had already purchased dicamba products for the current soy season could legally use them.

"Farmers across America have spent hard earned money on previously allowed crop protection tools. I encourage the EPA to use any available flexibilities to allow the continued use of already purchased dicamba products," Perdue said in a statement.

The EPA added restrictions on the use of dicamba in 2018 and the companies adapted as a result. Bernstein analyst Gunther Zechmann said there would therefore be little effect on dicamba volumes for next year's planting season.

"The company has already made label adjustments, which has therefore made the court opinion moot," he said in a note.

The decision could cost Bayer 30 million euros ($34 million) in lost earnings, Zechmann said.

Arkansas farmer Reed Storey said he was encouraged by the ruling, after his soybeans suffered damage from dicamba sprayed on neighboring fields from 2016 to 2018.

"It's a move in the right direction in getting the in-crop use of it stopped," he said.

Some farmers and seed dealers said the ruling could drive a shift away from Bayer's dicamba-resistant Xtend soybean seeds to Enlist E3 soybeans sold by Corteva.

Xtend soybeans account for more than half of U.S. soy plantings. Farmers turned to the product to protect themselves from dicamba sprayed by neighbors and after some weeds developed resistance to glyphosate.

The American Soybean Association trade group said in a statement it "regrets that the future of dicamba - a very effective weed management product when used responsibly - is on the line."

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :Bayer AGMonsanto

Next Story